natgillin/translations-raw huggingface dataset:
LAVENTAIR also demonstrated a greater increase from baseline in the proportion of days when no rescue medication was needed in all three studies (average within the range 17.6% to 21.5%) compared with tiotropium (average within the range 11.7% to 13.4%).
LAVENTAIR je u sva tri ispitivanja pokazao značajnije proporcionalno povećanje u danima, naspram početne vrijednosti kada nije bila potrebna primjena lijeka za hitno ublažavanje simptoma (prosjek u rasponu od 17,6% do 21,5%) u usporedbi s tiotropijem (prosjek u rasponu od 11,7% do 13,4%).
Laventair also increased FEV1 by an average of 95 ml more than vilanterol alone and by 52 ml more than umeclidinium bromide alone.
Laventair je također povećao FEV1 prosječno za do 95 ml više u odnosu na monoterapiju vilanterolom te za 52 ml više u odnosu na monoterapiju umeklidinijevim bromidom.
Laventair can only be obtained with a prescription.
Laventair se izdaje samo na liječnički recept.
LAVENTAIR contains lactose
LAVENTAIR sadrži laktozu
LAVENTAIR contains two active substances called umeclidinium and vilanterol.
LAVENTAIR sadrži dvije djelatne tvari koje se zovu umeklidinij i vilanterol.
Laventair contains two active substances.
Laventair sadrži dvije djelatne tvari.
LAVENTAIR demonstrated improvements in lung function (as defined by change from baseline in trough FEV1) in several studies.
LAVENTAIR je u nekoliko ispitivanja pokazao poboljšanja plućne funkcije (definirana promjenom najniže vrijednosti FEV1 u odnosu na početnu vrijednost).
Laventair is a medicine that contains the active substances umeclidinium bromide and vilanterol.
Laventair je lijek koji sadrži djelatne tvari umeklidinijev bromid i vilanterol.
LAVENTAIR is for inhalation use only.
LAVENTAIR se primjenjuje isključivo putem inhalacije.
LAVENTAIR is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
LAVENTAIR je indiciran kao bronhodilatator u terapiji održavanja u odraslih bolesnika s kroničnom opstruktivnom plućnom bolešću (KOPB) s ciljem ublažavanja simptoma.
LAVENTAIR is used to treat chronic obstructive pulmonary disease (COPD) in adults.
LAVENTAIR se koristi za liječenje kronične opstruktivne plućne bolesti (KOPB) u odraslih osoba.
LAVENTAIR reduced the use of rescue medication with salbutamol over Weeks 1-24 compared with placebo and umeclidinium (see Table 1) and demonstrated an increase from baseline in the proportion of days when no rescue medication was needed (on average 11.1%) compared with a decrease from baseline on placebo (on average 0.9%).
Primjena lijeka LAVENTAIR smanjila je uporabu salbutamola kao lijeka za hitno ublažavanje simptoma (engl. rescue medication) u razdoblju od 1-24 tjedna u usporedbi s placebom i umeklidinijem (vidjeti Tablicu 1) te pokazala proporcionalno povećanje u danima naspram početne vrijednosti, kada uporaba lijeka za hitno ublažavanje simptoma nije bila potrebna (u prosjeku 11,1%) u usporedbi sa smanjenjem naspram početne vrijednosti, kod placeba (u prosjeku 0, 9%).
LAVENTAIR should be administered once daily at the same time of the day each day to maintain bronchodilation.
LAVENTAIR treba primjenjivati jedanput na dan, svakoga dana u isto vrijeme, kako bi se održao bronhodilatacijski učinak.
LAVENTAIR should not be used to relieve a sudden attack of breathlessness or wheezing.
LAVENTAIR se ne smije primjenjivati za ublažavanje naglog napadaja nedostatka zraka ili piskanja pri disanju.
LAVENTAIR showed a statistically significant reduction in SGRQ total score compared with tiotropium in one of the three active-comparator studies (see Table 1).
LAVENTAIR je doveo do statistički značajnog smanjenja ukupnog SGRQ rezultata u usporedbi s tiotropijem u jednom od triju ispitivanja s aktivnim usporednim lijekom (vidjeti Tablicu 1).
Laventair umeclidinium bromide / vilanterol
Laventair umeklidinijev bromid / vilanterol
Laxatives.
Laksativi.
Lay
Nesenje:
Lay language version of the healthcare professional A4 laminated titration guide;
Inačicu vodiča za titraciju doze za zdravstvenog radnika na plastificiranom kartonu A4 formata pisanu laičkim jezikom;
Lay out all the pieces of your Tolero nebuliser handset on a clean, dry paper or cloth towel.
Položite sve dijelove svog ručnog atomizatora Tolero na čisti, suhi papir ili ručnik.
Lay out and confirm that components listed below are provided:
Izložite i provjerite da su niže navedeni dijelovi priloženi:
Lay the pre-filled pen on a flat clean surface and wait until it reaches room temperature (but not more than 25oC).
Položite napunjenu brizgalicu na ravnu, čistu površinu i pričekajte da dostigne sobnu temperaturu (ali ne iznad 25ºC).
Lay:
Nesenje
LCE treatment was converted into Numient over a 6-week period.
Liječenje LCE-om prevedeno je u Numient tijekom 6- tjednog razdoblja.
LCS symptom improvement rate a %
Stopa poboljšanja simptoma prema LCSa
LD-Dex (40 mg) was administered once per day on Days 1, 8, 15 and 22 of a 28-day cycle.
LD-Dex (40 mg) primjenjivao se jedanput na dan 1., 8., 15. i dana 28-dnevnog ciklusa.
LDH level at 6 months (median, U/L)
Razina LDH nakon 6 mjeseci (medijan, U/l)
LDH level at baseline (median , U/L)
Razina LDH na početku (medijan, U/l)
LDH levels at end of study (median, U/L)
LDH razine na kraju ispitivanja (medijan, U/l)
LDL cholesterol is often called ‘bad’ cholesterol because it can build up in the walls of your arteries and form plaque.
LDL kolesterol često se naziva "lošim" kolesterolom jer se može nakupljati u stijenki arterija i tamo formirati naslage (plak).
LDL cholesterol is often called ‘bad’ cholesterol because it can build up in the walls of your arteries and form plaque.
LDL kolesterol često se naziva "lošim" kolesterolom zato što se može nakupiti u stijenkama arterija i stvoriti plak.
LDL-C (%)
LDL- C (%)
LDL-C (ITT )a
LDL-C (ITT)a
LDL-C (on treatment)b
LDL-C (liječena populacija)b
LDL-C, direct (mg/dL)
LDL kolesterol, izravno (mg/dl)
LDL-C/HDL-C
LDL-K/HDL-K
LDL-cholesterol, mean % change from baseline
LDL kolesterol, srednja vrijednost promjene od početne vrijednosti u
LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C.
LDLR je primarni receptor koji odstranjuje cirkulirajući LDL i stoga pad vrijednosti LDLR-a uzrokovan djelovanjem PCSK9 dovodi do viših vrijednosti LDL-C u krvi.
LDPE bottle
LDPE boca
LDPE BOTTLE 30 ml LABEL
OZNAKA ZA LDPE BOCU 30 ml
LDPE Syringe
Ambalaža
LDV/SOF+RBV
LDV/SOF
LDV/SOF+RBV
LDV/SOF+ RBV
LE18 4YL, United Kingdom
LE18 4YL, Ujedinjeno Kraljevstvo
LEAD POT
OLOVNA POSUDA
LEAD POT
OLOVNI SPREMNIK
Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer cap.
Uvedite vrh igle u vanjski zatvarač igle na ravnoj površini ne dodirujući iglu ili vanjski zatvarač.
Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer needle cap.
Uvedite vrh igle u vanjski zatvarač igle na ravnoj površini ne dodirujući iglu ili vanjski zatvarač igle.
Lead the needle tip into the outer needle cap on a flat surface.
Na ravnoj površini uvedite vrh igle u vanjski zatvarač igle.
lead to an increase of
metabolita) potencijalno može dovesti do povećanja nuspojava
lead to an increase of rifabutin related adverse
metabolita) potencijalno može dovesti do povećanja nuspojava
leading to a risk of rifamycin resistance and a treatment failure.
bi moglo dovesti do rizika od razvoja rezistencije na rifampicin i neuspješnog liječenja.
Leaflets giving detailed instructions for use of EVICEL in conjunction with the application device and optional accessory tips are provided with the package of the application device and of the accessory tips.
U pakiranjima aplikatora i dodatnih nastavaka nalaze se detaljne upute za primjenu lijeka EVICEL pomoću aplikatora i dodatnih nastavaka.
leakage of the drug into the surrounding tissue at the site of injection, which may cause swelling or redness swelling of arms and/or legs
istjecanje lijeka u okolno tkivo na mjestu injekcije koje može prouzročiti oticanje ili crvenilo oticanje ruku i/ili nogu
leakage of the infusion to the surrounding tissue (extravasation), causing skin inflammation (infusion site dermatitis) and shedding (infusion site desquamation) or injection site ulcers tissue damage around tumours of the lymph system and complications due to swelling of such tumours
izlijevanje infuzije u okolna tkiva (ekstravazacija) koja izaziva upalu kože (dermatitis na mjestu infuzije), ljuštenje kože (deskvamacija na mjestu infuzije) ili vrijed na mjestu infuzije oštećenja tkiva oko tumora limfnog sustava i komplikacije zbog oticanja takvih tumora
leakage of urine
nemogućnost zadržavanja mokraće
leaking from tiny blood vessels, rapid breathing, nosebleeds, breathing difficulties, breathlessness, cough;
krvarenje iz malih krvnih žila, ubrzano disanje, krvarenje iz nosa, otežano disanje, nedostatak zraka, kašalj;
leaking milk from the breasts in girls
curenje mlijeka iz dojki kod djevojaka
Learn to deal with diet-related treatment effects
Naučite kako se nositi s učincima lijeka povezanima s prehranom
Learning how to use the pre-filled pens
Naučite kako koristiti napunjene brizgalice
least 1 day, until healing is achieved.
najmanje 1 dana, sve do zacjeljenja rane.
least 24 to 48 hours before the chemotherapy and radiotherapy starts.
Posljednja od tri doze koja se daje prije kemoterapije i zračenja mora se dati najmanje 24 do 48 sati prije početka kemoterapije i zračenja.
least 4 hours.
4 sata.
least 75% of the usual 300 mg/day
rifabutina za najmanje 75% od
Least Square Means (SE)
Srednja vrijednost najmanjih kvadrata (standardna pogreška)
Least Squares Mean Ratio (90%CI)
Omjer srednjih vrijednosti dobivenih metodom najmanjeg kvadrata (90%CI)
Leave a gap of at least 3 months after your last treatment before you start breast-feeding.
Između dojenja i zadnje terapije lijekom RoActemra mora proći najmanje 3 mjeseca.
Leave Aldara cream on the skin for about 8 hours.
Ostavite da krema Aldara djeluje oko 8 sati.
Leave Aldara cream on the skin for about 8 hours.
Ostavite kremu Aldara da djeluje oko 8 sati.
Leave Aldara cream on the warts for 6 to 10 hours.
Ostavite da krema Aldara djeluje na bradavice 6 do 10 sati.
Leave Avonex Pen to warm up
Ostavite Avonex Pen da se ugrije
Leave it at room temperature for half an hour.
Ostavite ga na sobnoj temperaturi pola sata.
Leave it at room temperature for half an hour.
Ostavite je na sobnoj temperaturi pola sata.
Leave it to dry in the air - lay it on its side with the mouth-piece open.
Pustite da se osuši na zraku – položite ga na bok s otvorenim nastavkom za usta.
Leave Plegridy to warm to room temperature before injecting.
Ostavite Plegridy da se ugrije na sobnu temperaturu prije injiciranja.
Leave the adaptor in place and replace cap on bottle.
Nastavak ostavite na svom mjestu, a bocu zatvorite zatvaračem.
Leave the adaptor in place and replace cap on bottle.
Ostavite adaptor na mjestu i vratite zatvarač boce.
Leave the filter needle in the vial and disconnect the syringe from the filter needle.
Iglu s filterom ostavite u bočici, a štrcaljku odvojite od igle s filterom.
Leave the inner needle shield in position.
Ostavite unutarnji štitnik za iglu na mjestu.
Leave the needle in the vial.
Ostavite iglu u bočici.
Leave the needle shield on the needle
Ostavite kapicu igle na igli.
Leave the needle under the skin for at least 6 seconds to make sure you get your full dose.
Zadržite iglu pod kožom najmanje 6 sekundi kako biste bili sigurni da ste primili cijelu dozu.
Leave the patch on your skin for 24 hours, then remove it and apply a new one.
Ostavite flaster na koži 24 sata i onda ga odstranite i primijenite novi.
Leave the patch on your skin for 24 hours, then remove it and apply a new one.
Ostavite flaster na koži 24 sata onda ga odstranite i primijenite novi.
Leave the patch on your skin for 24 hours, then remove it and apply a new one.
Ostavite flaster na koži 24 sata, onda ga odstranite i primijenite novi.
Leave the plunger rod untouched in the carton.
Potisni klip ostavite u kutiji.
leave the pre-filled pen in direct sunlight.
izlagati napunjenu brizgalicu izravnoj sunčevoj svjetlosti.
Leave the reconstitution needle and empty syringe in the vial.
Iglu za pripremu otopine i praznu štrcaljku ostavite u bočici.
Leave the Repatha pre-filled syringe exposed to direct sunlight.
izlagati Repatha napunjenu štrcaljku izravnoj sunčevoj svjetlosti.
Leave the syringe at room temperature for approximately 30 minutes or hold the pre-filled syringe gently in your hand for a few minutes.
Ostavite štrcaljku na sobnoj temperaturi približno 30 minuta ili nježno držite napunjenu štrcaljku u ruci nekoliko minuta.
Leave the syringe in place.
Ostavite štrcaljku na mjestu.
Leave the syringe in the rubber stopper.
Ostavite štrcaljku u gumenom čepu.
Leave the syringe to warm up
Ostavite da se štrcaljka ugrije
Leave the vial and syringe to stand for 15 minutes.
Ostavite bočicu i štrcaljku da odstoje 15 minuta.
Leave them to stand for 5 minutes.
Ostavite ih da odstoje 5 minuta.
Lecithin Oleic acid
Lecitin
Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily)3
Ledipasvir (90 mg jedanput na dan)/ sofosbuvir (400 mg jedanput na dan), emtricitabin (200 mg jedanput na dan)/ tenofoviralafenamid (10 mg jedanput na dan)3
Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (25 mg once daily)4
Ledipasvir (90 mg jedanput na dan)/ sofosbuvir (400 mg jedanput na dan), emtricitabin (200 mg jedanput na dan)/ tenofoviralafenamid (25 mg jedanput na dan)4
Ledipasvir and sofosbuvir are substrates of drug transporter P-gp and BCRP while GS-331007 is not.
Ledipasvir i sofosbuvir supstrati su prijenosnika lijekova P-gp i BCRP, dok GS-331007 to nije.
ledipasvir AUC 1.92 (1.77-2.07) ↑ ledipasvir Cmax 1.81 (1.69-2.94) ↑ ledipasvir Cmin not studied simeprevir AUC 2.69 (2.44-2.96) ↑ simeprevir Cmax 2.61 (2.34-2.86) ↑ simeprevir Cmin not studied
ledipasvir AUC 1,92 (1,77-2,07) ↑ ledipasvir Cmax 1,81 (1,69-2,94) ↑ ledipasvir Cmin nije ispitano simeprevir AUC 2,69 (2,44-2,96) ↑ simeprevir Cmax 2,61 (2,34-2,86) ↑ simeprevir Cmin nije ispitano
Ledipasvir AUC is dose proportional over the dose range of 3 to 100 mg.
AUC ledipasvira proporcionalna je dozi u rasponu doza od 3 do 100 mg.
Ledipasvir is a HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA
Ledipasvir je inhibitor HCV-a usmjeren na protein HCV NS5A, koji je neophodan kako za replikaciju
Ledipasvir is an in vitro inhibitor of drug transporter P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of co-administered substrates for these transporters.
Ledipasvir je in vitro inhibitor prijenosnika lijekova P-gp i proteina rezistencije karcinoma dojke na lijekove (BCRP) te može povećati crijevnu apsorpciju istovremeno primijenjenih supstrata ovih prijenosnika.
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Emtricitabine/Rilpivirine/ Tenofovir disoproxil fumarate (200 mg/25 mg/300 mg once daily)
(90 mg/400 mg jedanput dnevno)/ emtricitabin/rilpivirin/ tenofovirdizoproksilfumarat (200 mg/25 mg/300 mg jedanput dnevno)
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Rilpivirine
Ledipasvir/Sofosbuvir (90 mg/400 mg jedanput na dan)/ rilpivirin
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Tenofovir alafenamide
Ledipasvir/Sofosbuvir (90 mg/400 mg jedanput na dan)/ tenofoviralafenamid
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) +
Ledipasvir/sofosbuvir (90 mg/400 mg q.d.) + darunavir/ritonavir
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (600 mg/200 mg/300 mg q.d.)
Ledipasvir/sofosbuvir (90 mg/400 mg q.d.) + efavirenz/emtricitabin/tenofovir- dizoproksilfumarat (600 mg/200 mg/300 mg q.d.)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Emtricitabine/Rilpivirine/Tenofo vir disoproxil fumarate (200 mg/25 mg/300 mg q.d.)
(90 mg/400 mg q.d.) + emtricitabin/rilpivirin/tenofovir- dizoproksilfumarat (200 mg/25 mg/300 mg q.d.)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Emtricitabine/Rilpivirine/Tenofo vir disoproxil fumarate (200 mg/25 mg/300 mg q.d.)
Sofosbuvir (400 mg q.d.) + efavirenz/emtricitabin/tenofovir- dizoproksilfumarat (600 mg/200 mg/300 mg q.d.)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate (200 mg/25 mg/300 mg q.d.)
Ledipasvir/sofosbuvir (90 mg/400 mg q.d.) + emtricitabin/rilpivirin/tenofovir- dizoproksilfumarat (200 mg/25 mg/300 mg q.d.)
leep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract
indrom apneje pri spavanju, hiperventilacija, aspiracijska pneumonija, kongestija dišnih puteva, disfonija
leep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract
neonatalni sindrom ustezanja lijeka (vidjeti dio 4.6)c
leep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract congestion, dysphonia
urinarna inkontinencija, polakizurija, urinarna retencija, dizurija
leep disorder
poremećaj spavanja
leep disorder,
rijetko
leep disorder, confusional state, libido decreased, anorgasmia, nervousness, nightmare
poremećaj spavanja, stanje konfuzije, smanjen libido, anorgazmija, nervoza, noćne more
leep disorder, decreased sexual drive, nervousness, nightmares
poremećaj spavanja, smanjena spolna želja, nervoza, noćne more
leep disorder, elated mood (mania), confusion, decreased sexual drive, nervousness, nightmares tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body).
poremećaj spavanja, ushićeno raspoloženje (manija), zbunjenost, smanjena spolna želja, nervoza, noćne more tardivna diskinezija (trzajni pokreti lica, jezika i drugih dijelova tijela koje ne možete kontrolirati).
leep disorder, mania, confusional state, libido decreased, nervousness, nightmare
poremećaj spavanja, manija, stanje konfuzije, smanjen libido, nervoza, noćne more
leep disorders
poremećaj spavanja
leep disorders
poremećaji spavanja
leep disorders (abnormal sleeping);
poremećaji sna (promjene spavanja);
leep disorders including inability to get adequate sleep
poremećaji spavanja uključujući i nedostatak sna
leep disorders, abnormal drowsiness, confusion, depression, anxiety, agitation
poremećaji spavanja, neuobičajena omamljenost, zbunjenost, depresija, nemir, razdražljivost
leep disturbances
poremećaji spavanja
leep disturbances including nightmares
poremećaji sna uključujući noćne more
leep interruptions
isprekidan san
leep interruptions;
isprekidan san,
leep problems
teškoće sa spavanjem
leep problems, feeling anxious, emotional instability, or mood swings
poremećaj spavanja, osjećaj tjeskobe, emotivna labilnost ili promjene raspoloženja
leep problems, feeling anxious, emotional instability, or mood swings
poremećaj spavanja, osjećaj tjeskobe, emotivna nestabilnost ili promjene raspoloženja
leep problems, somnolence,
poremećaji spavanja, izrazita pospanost,
leep-inducing, prevention of seizures
induciranje sna, prevencija napadaja
leepiness
pospanost
leepiness
razdražljivost
leepiness (somnolence)
pospanost (somnolencija)
leepiness (somnolence)  neck pain
pospanost (izrazita pospanost)  bol u vratu
leepiness abnormal taste.
pospanost abnormalan okus.
leepiness or drowsiness fever (temperature 38°C or higher) pain, redness, swelling at the injection site
pospanost ili omamljenost vrućica (temperatura od 38°C ili viša) bol, crvenilo, oticanje na mjestu injiciranja
leepiness or trouble sleeping
pospanost ili poteškoće sa spavanjem
leepiness,
pospanost,
leepiness, dizziness, bone pain, breast pain, muscle pain, leg cramps or swelling, general swelling, inflammation of the retina (the light-detecting membrane of the eye), increased tear production, blurred vision, feeling of pins and needles or pain in hands and feet;
pospanost, omaglica, bolovi u kostima, bolovi u dojkama, bolovi u mišićima, grčevi ili otok nogu, opća otečenost, upala mrežnice (dio oka koji reagira na svjetlo), pojačano lučenje suza, zamagljen vid, osjećaj trnaca i mravaca ili bolovi u šakama i stopalima;
leepiness, dizziness, headache
pospanost, omaglica, glavobolja
leepiness, drowsy
omamljenost, pospanost
leepiness, falling asleep suddenly without warning, difficulty in sleeping, sleep problems, having unusual dreams
pospanost, iznenadno usnivanje bez upozorenja, teškoće s usnivanjem, poremećaji spavanja, neobični snovi
leepiness, sedation, excessive tiredness, weakness, migraine, numbness, swelling of arms or legs, drug withdrawal syndrome (may manifest by the occurrence of the following side effects nausea, vomiting, diarrhoea, anxiety, chills, tremor, and sweating), shaking, falls, chills
pospanost, sedacija, prekomjerni umor, slabost, migrena, utrnulost, oticanje ruku i nogu, sindrom ustezanja lijeka (može se očitovati nastankom sljedećih nuspojava: mučnina, povraćanje, proljev, tjeskoba, zimice, nevoljno drhtanje i znojenje), tresavica, padovi, zimica
leepiness, tiredness, light-headedness and less frequently confusion,
pospanost, umor, omaglica i rjeđe smetenost,
leepiness, tiredness, light-headedness and less frequently confusion,
pospanost, umor, ošamućenost i rjeđe smetenost,
leepiness;
pospanost;
leeping more than normal (hypersomnia)
prekomjerno spavanje (hipersomnija)
leeping pills (e.g. alprazolam, zolpidem) and also midazolam administered by injection;
pilule za spavanje (npr. alprazolam, zolpidem) i midazolam u injekcijama;
leeplessness
nesanica
leeplessness
pospanost
leeplessness (insomnia), depression
nesanica (insomnija), depresij
leeplessness (insomnia), depression
nesanica (insomnija), depresija
leeplessness (insomnia), depression
nesanica, depresija
leeplessness enlargement of the male breast
nesanica povećanje dojki kod muškaraca
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid djeluje inhibirajući enzim naziva „dihidroorotat dehidrogenaza“, koji je neophodan za diobu limfocita.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid djeluje tako što inhibira enzim naziva „dihidroorotat dehidrogenaza“, koji je neophodan za diobu limfocita.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid to čini blokadom enzima zvanog „dihidroorotat dehidrogenaza” koji je potreban za razmnožavanje limfocita.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomide to čini blokadom enzima zvanog „dihidroorotat dehidrogenaza” koji je potreban za razmnožavanje limfocita.
Leflunomide is effective in animal models of arthritis and of other autoimmune diseases and transplantation, mainly if administered during the sensitisation phase.
Leflunomid je djelotvoran na životinjskim modelima artritisa i ostalih autoimunih bolesti te transplantacije, uglavnom ako se primjenjuje u fazi senzibilizacije.
Leflunomide is effective in animal models of arthritis and of otherautoimmune diseases and transplantation, mainly if administered during the sensit isation phase.
Leflunomid je učinkovit na životinjskim modelima artritisa i ostalih autoimunih bolesti te transplantacije uglavnom ako se primjenjuje u fazi senzibilizacije.
Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran u liječenju odraslih bolesnika s aktivnim reumatoidnim artritisom kao antireumatik koji modificira tijek bolesti (DMARD od engl. disease-modifying antirheumatic drug), aktivnim psorijatičnim artritisom.
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran u liječenju odraslih bolesnika s: aktivnim reumatoidnim artritisom kao antireumatik koji modificira tijek bolesti (DMARD od engl. disease-modifying antirheumatic drug), aktivnim psorijatičnim artritisom.